Key result
RAS inhibitors cut all-cause mortality ~24% vs no RAS inhibitors after TAVR.
Why the study?
To evaluate the clinical outcomes of RAS inhibitors for patients after TAVR.
Does renin-angiotensin system (RAS) inhibitor therapy reduce all-cause mortality, cardiovascular death, and heart failure readmission in patients after transcatheter aortic valve replacement (TAVR)?
Meta-Analysis (n=32,585)
Yes
Does renin-angiotensin system (RAS) inhibitor therapy reduce all-cause mortality, cardiovascular death, and heart failure readmission in patients after transcatheter aortic valve replacement (TAVR)?
In patients undergoing TAVR, treatment with RAS inhibitors is associated with significantly lower rates of all-cause mortality, cardiovascular death, and heart failure readmission.
May support RAS inhibitor use after TAVR; confirms mortality benefit in meta-analysis of available data.
Aims: The objective of our systematic reviews and meta-analysis is to evaluate the clinical outcomes of RAS inhibitors for patients after TAVR. Methods and Conclusions: In conclusion, our systematic reviews and meta-analysis demonstrated that RAS inhibitors could improve the clinical outcomes for patients after TAVR. Further large and high-quality trials should be conducted to support the use of RAS inhibitors for patients after TAVR.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a meta-analysis in Aortic stenosis post-transcatheter aortic valve replacement (TAVR) (n=32,585). Reni-angiotensin system (RAS) inhibitors vs. No RAS inhibitors was evaluated on All-cause mortality (RR 0.76, 95% CI 0.68-0.86, p=<0.01). RAS inhibitors significantly reduced all-cause mortality by 24% (RR 0.76) compared to no RAS inhibitors in patients after transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: